Efficacy of subsequent therapies in patients with advanced ovarian cancer who relapse after first-line olaparib maintenance: results of the PAOLA-1/ENGOT-ov25 trial.

Harter P, Marth C, Mouret-Reynier MA, Cropet C, Lorusso D, Guerra-Alía EM, Matsumoto T, Vergote I, Colombo N, Mäenpää J, Lebreton C, de Gregorio N, Mosconi AM, Rubio-Pérez MJ, Bourgeois H, Fasching PA, Cecere SC, Hardy-Bessard AC, Denschlag D, de Percin S, Hanker L, Favier L, Bauerschlag D, Desauw C, Hillemanns P, Largillier R, Sehouli J, Grenier J, Pujade-Lauraine E, Ray-Coquard I, PAOLA-1/ENGOT-ov25 investigators

Open source

DOI: 10.1016/j.annonc.2024.10.828
Published: 2025 Feb
Container: Annals of oncology : official journal of the European Society for Medical Oncology
Publisher: Not recorded
Open access: unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/j.annonc.2024.10.828,
  title = {Efficacy of subsequent therapies in patients with advanced ovarian cancer who relapse after first-line olaparib maintenance: results of the PAOLA-1/ENGOT-ov25 trial.},
  author = {Harter P and Marth C and Mouret-Reynier MA and Cropet C and Lorusso D and Guerra-Alía EM and Matsumoto T and Vergote I and Colombo N and Mäenpää J and Lebreton C and de Gregorio N and Mosconi AM and Rubio-Pérez MJ and Bourgeois H and Fasching PA and Cecere SC and Hardy-Bessard AC and Denschlag D and de Percin S and Hanker L and Favier L and Bauerschlag D and Desauw C and Hillemanns P and Largillier R and Sehouli J and Grenier J and Pujade-Lauraine E and Ray-Coquard I and PAOLA-1/ENGOT-ov25 investigators},
  year = {2025},
  journal = {Annals of oncology : official journal of the European Society for Medical Oncology},
  doi = {10.1016/j.annonc.2024.10.828},
  url = {https://doi.org/10.1016/j.annonc.2024.10.828}
}

RIS

TY  - JOUR
TI  - Efficacy of subsequent therapies in patients with advanced ovarian cancer who relapse after first-line olaparib maintenance: results of the PAOLA-1/ENGOT-ov25 trial.
AU  - Harter P
AU  - Marth C
AU  - Mouret-Reynier MA
AU  - Cropet C
AU  - Lorusso D
AU  - Guerra-Alía EM
AU  - Matsumoto T
AU  - Vergote I
AU  - Colombo N
AU  - Mäenpää J
AU  - Lebreton C
AU  - de Gregorio N
AU  - Mosconi AM
AU  - Rubio-Pérez MJ
AU  - Bourgeois H
AU  - Fasching PA
AU  - Cecere SC
AU  - Hardy-Bessard AC
AU  - Denschlag D
AU  - de Percin S
AU  - Hanker L
AU  - Favier L
AU  - Bauerschlag D
AU  - Desauw C
AU  - Hillemanns P
AU  - Largillier R
AU  - Sehouli J
AU  - Grenier J
AU  - Pujade-Lauraine E
AU  - Ray-Coquard I
AU  - PAOLA-1/ENGOT-ov25 investigators
PY  - 2025
JO  - Annals of oncology : official journal of the European Society for Medical Oncology
DO  - 10.1016/j.annonc.2024.10.828
UR  - https://doi.org/10.1016/j.annonc.2024.10.828
ER  -

APA

P, H., C, M., MA, M., C, C., D, L., EM, G., T, M., I, V., N, C., J, M., C, L., N, D. G., AM, M., MJ, R., H, B., PA, F., SC, C., AC, H., D, D., S, D. P., L, H., L, F., D, B., C, D., P, H., R, L., J, S., J, G., E, P., I, R., & investigators, P. (2025). Efficacy of subsequent therapies in patients with advanced ovarian cancer who relapse after first-line olaparib maintenance: results of the PAOLA-1/ENGOT-ov25 trial.. Annals of oncology : official journal of the European Society for Medical Oncology. https://doi.org/10.1016/j.annonc.2024.10.828

Source records

pubmed · retrieved 2026-09-26T14:56:16.524Z